JHVEPhoto / Shutterstock.com
19 March 2019Americas
Teva enters settlement with Novo Nordisk to sell Victoza generic
Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza (liraglutide).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
24 March 2022 Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Editor's picks
Editor's picks
Big Pharma
4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
24 March 2022 Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Big Pharma
4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
24 March 2022 Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.